tbuckley/cabot-search huggingface dataset:
Phase II clinical trial of <i>uncaria tomentosa</i> (cat´s claw) in patients with advanced solid tumors.
Authors: Larissa Carvalho Lopes De Paula, Fernando Fonseca, Fábio Ferreira Perazzo, Felipe Melo Cruz, Daniel de Iracema Gomes Cubero, Damila Cristina Trufelli, Suelen Patrícia dos Santos Martins, Patricia Xavier Santi, Eliana Araújo da Silva, Auro Del Giglio
Journal: Journal of Clinical Oncology (2014)

9557 Background: Cat’s claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Methods: This prospective phase II study assessed the effects of a 100-mg dose of a dry extract of U. tomentosathree times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. We used the EORTC QLQ C30 and FACIT-F questionnaires to assess the participants´ quality of life, the HADS questionnaire to assess their anxiety and depression and the Pittsburgh index (PSQI) to assess their sleep quality. In addition, several biochemical and inflammatory parameters were analyzed. Results: We recruited 51 volunteers; their median age was 64 (33-85) years old, and 47% were females. Their scores on the Karnofsky scale were equal to or less than 80% for more than 65% of the volunteers. Treatment caused an improvement in the patients’ overall quality of life (p= 0.0411) and social functioning (p= 0.0341), as assessed by EORTC QLQ C-30, and a reduction of fatigue (p= 0.0496) by the Chalder Fatigue Questionnaire. None of the biochemical or inflammatory parameters assessed (interleukins 1 and 6, C-reactive protein, tumor necrosis factor alpha, erythrocyte sedimentation rate and alpha-1-acid glycoprotein) exhibited significant changes. No tumor response was detected according to the RECIST criteria; however, the disease stabilized for more than eight months in four participants. The medication was well tolerated by most patients. Conclusions: We conclude that use of cat´s claw might be beneficial for patients with advanced cancer because it could improve their quality of life and reduce fatigue. The mechanism of this action does not seem to be related to the anti-inflammatory properties of this plant. Clinical trial information: NCT02045719.
A transit-amplifying population underpins the efficient regenerative capacity of the testis
Authors: Claudia Carrieri, Stefano Comazzetto, Amit Grover, Marcos Morgan, Andreas Buness, Claus Nerlov, Dónal O’Carroll
Journal: The Journal of Experimental Medicine (2017)

The spermatogonial stem cell (SSC) that supports spermatogenesis throughout adult life resides within the GFRα1-expressing A type undifferentiated spermatogonia. The decision to commit to spermatogenic differentiation coincides with the loss of GFRα1 and reciprocal gain of Ngn3 (Neurog3) expression. Through the analysis of the piRNA factor Miwi2 (Piwil4), we identify a novel population of Ngn3-expressing spermatogonia that are essential for efficient testicular regeneration after injury. Depletion of Miwi2-expressing cells results in a transient impact on testicular homeostasis, with this population behaving strictly as transit amplifying cells under homeostatic conditions. However, upon injury, Miwi2-expressing cells are essential for the efficient regenerative capacity of the testis, and also display facultative stem activity in transplantation assays. In summary, the mouse testis has adopted a regenerative strategy to expand stem cell activity by incorporating a transit-amplifying population to the effective stem cell pool, thus ensuring rapid and efficient tissue repair.
A new form of IRIDA due to combined heterozygous mutations of TMPRSS6 and ACVR1A encoding the BMP receptor ALK2
Authors: Alessia Pagani, Silvia Colucci, Renata Bocciardi, Marta Bertamino, Carlo Dufour, Roberto Ravazzolo, Laura Silvestri, Clara Camaschella
Journal: Blood (2017)
Treatment of Opioid Use Disorder During Pregnancy and Cases of Neonatal Abstinence Syndrome
Authors: Davida M. Schiff, Stephen W. Patrick
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
MiR-200c Inhibits the Tumor Progression of Glioma via Targeting Moesin
Authors: Yuanyuan Qin, Weilong Chen, Bingjie Liu, Lei Zhou, Lu Deng, Wanxiang Niu, Dejun Bao, Chuandong Cheng, Dongxue Li, Suling Liu, Chaoshi Niu
Journal: Theranostics (2017)

We attempt to demonstrate the regulatory role of miR-200c in glioma progression and its mechanisms behind.Here, we show that miR-200c expression was significantly reduced in the glioma tissues compared to paratumor tissues, especially in malignant glioma.Exogenous overexpression of miR-200c inhibited the proliferation and invasion of glioma cells.In addition, the in vivo mouse xenograft model showed that miR-200c inhibited glioma growth and liver metastasis, which is mainly regulated by targeting moesin (MSN).We demonstrated that the expression of MSN in glioma specimens were negatively correlated with miR-200c expression, and MSN overexpression rescued the phenotype about cell proliferation and invasion induced by miR-200c.Moreover, knockdown of MSN was able to mimic the effects induced by miR-200c in glioma cells.These results indicate that miR-200c plays an important role in the regulation of glioma through targeting MSN.
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
Authors: George Somlo, Paul Henry Frankel, Thehang H. Luu, Cynthia Ma, Banu Arun, Agustin Garcia, Tessa Cigler, Leah Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy Jerome Moynihan, Linda T. Vahdat, Matthew P. Goetz, Arti Hurria, Joanne E. Mortimer, David R. Gandara, Alice Chen, Jeffrey N. Weitzel
Journal: Journal of Clinical Oncology (2014)

1021 Background: We reported on a phase I trial showing 54% confirmed partial response (PR) with carb + vel. Here we describe single agent vel activity and, upon progression, the feasibility and efficacy of continuing administration of vel + carb. Methods: Pts with MBC with BRCA1 or 2 mutations, an ECOG performance status of ≤ 2, and measurable disease were eligible. Prior PARP-inhibitor therapy (Rx) , platinum Rx for MBC, or central nervous system metastasis requiring Rx were exclusions. Vel was administered orally at 400 mg twice daily (BID). Cohorts (BRCA1 and BRCA2) were studied independently: 2 or more PRs to vel out of 10 pts were required to proceed to accrual of 22 pts per cohort. Upon progression, carb (AUC of 5) iv every 21 days, and vel 150 mg orally BID were prescribed. Results: Between 10/2012 and 1/2014, 44 pts enrolled (41 treated) carrying BRCA1 (N=21) or BRCA2 (N=20) mutations. The median age was 43-years (range; 28-68); 50% of pts had hormone receptor + BC. Pts received 3 prior chemo-regimens (0-7). The current PR rate in pts with at least 4 cycles of follow-up is 2/12 (17%) for BRCA1 and 3/13 (23%) for BRCA2. Three pts withdrew from treatment during the first cycle of vel due to grade 2 seizure (1), grade 3 thrombocytopenia (PLT [1]), grade 2 PLT and neutropenia (1). Time to failure (TTF) on vel is 2.0 months (0-10.5+), and 5.1 months (0.9-10.3+) for the two cohorts (BRCA1, BRCA2, respectively). Twenty pts are still on vel (8 BRCA1, 12 BRCA2). Of the 10 pts to proceed to vel + carb so far, 1 PR in a BRCA1 pt was observed. Conclusions: Vel is active when given at 400 mg BID daily. Further trials are indicated to assess its benefit whether in combination or as a single agent in both BRCA1 and BRCA2-associated BC. Clinical trial information: NCT01149083.
Elongated Nanoparticle Aggregates in Cancer Cells for Mechanical Destruction with Low Frequency Rotating Magnetic Field
Authors: Yajing Shen, Congyu Wu, Taro Q. P. Uyeda, Gustavo R. Plaza, Bin Liu, Yu Han, Maciej S. Lesniak, Yu Cheng
Journal: Theranostics (2017)

Magnetic nanoparticles (MNPs) functionalized with targeting moieties can recognize specific cell components and induce mechanical actuation under magnetic field.Their size is adequate for reaching tumors and targeting cancer cells.However, due to the nanometric size, the force generated by MNPs is smaller than the force required for largely disrupting key components of cells.Here, we show the magnetic assembly process of the nanoparticles inside the cells, to form elongated aggregates with the size required to produce elevated mechanical forces.We synthesized iron oxide nanoparticles doped with zinc, to obtain high magnetization, and functionalized with the epidermal growth factor (EGF) peptide for targeting cancer cells.Under a low frequency rotating magnetic field at 15 Hz and 40 mT, the internalized EGF-MNPs formed elongated aggregates and generated hundreds of pN to dramatically damage the plasma and lysosomal membranes.The physical disruption, including leakage of lysosomal hydrolases into the cytosol, led to programmed cell death and necrosis.Our work provides a novel strategy of designing magnetic nanomedicines for mechanical destruction of cancer cells.
Accuracy of diagnosing invasive colorectal cancer using computer-aided endocytoscopy
Authors: Kenichi Takeda, Shin-ei Kudo, Yuichi Mori, Masashi Misawa, Toyoki Kudo, Kunihiko Wakamura, Atsushi Katagiri, Toshiyuki Baba, Eiji Hidaka, Fumio Ishida, Haruhiro Inoue, Masahiro Oda, Kensaku Mori
Journal: Endoscopy (2017)

Abstract Background and study aims Invasive cancer carries the risk of metastasis, and therefore, the ability to distinguish between invasive cancerous lesions and less-aggressive lesions is important. We evaluated a computer-aided diagnosis system that uses ultra-high (approximately × 400) magnification endocytoscopy (EC-CAD). Patients and methods We generated an image database from a consecutive series of 5843 endocytoscopy images of 375 lesions. For construction of a diagnostic algorithm, 5543 endocytoscopy images from 238 lesions were randomly extracted from the database for machine learning. We applied the obtained algorithm to 200 endocytoscopy images and calculated test characteristics for the diagnosis of invasive cancer. We defined a high-confidence diagnosis as having a ≥ 90 % probability of being correct. Results Of the 200 test images, 188 (94.0 %) were assessable with the EC-CAD system. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were 89.4 %, 98.9 %, 94.1 %, 98.8 %, and 90.1 %, respectively. High-confidence diagnosis had a sensitivity, specificity, accuracy, PPV, and NPV of 98.1 %, 100 %, 99.3 %, 100 %, and 98.8 %, respectively. Conclusion: EC-CAD may be a useful tool in diagnosing invasive colorectal cancer.
Maternal colonization with Staphylococcus aureus and Group B streptococcus is associated with colonization in newborns
Authors: A. Roca, A. Bojang, B. Camara, C. Oluwalana, K. Lette, P. West, U. D'Alessandro, C. Bottomley
Journal: Clinical Microbiology and Infection (2017)

Although Staphylococcus aureus and Group B streptococcus (GBS) are major causes of neonatal sepsis in sub-Saharan Africa, it is unclear how these bacteria are transmitted to the neonate.In a cohort of 377 Gambian women and their newborns, nasopharyngeal swabs were collected at delivery (day 0), and 3, 6, 14 and 28 days later. Breast milk samples and vaginal swabs were collected from the mother. Staphylococcus aureus and GBS were isolated using conventional microbiological methods.Most women were carriers of S. aureus (264 out of 361 with all samples collected, 73.1%) at some point during follow up and many were carriers of GBS (114 out of 361, 31.6%). Carriage of S. aureus was common in all three maternal sites and GBS was common in the vaginal tract and breast milk. Among newborns, carriage of S. aureus peaked at day 6 (238 out of 377, 63.1%) and GBS at day 3 (39 out of 377, 10.3%). Neonatal carriage of S. aureus at day 6 was associated with maternal carriage in the breast milk adjusted OR 2.54; 95% CI 1.45-4.45, vaginal tract (aOR 2.55; 95% CI 1.32-4.92) and nasopharynx (aOR 2.49; 95% CI 1.56-3.97). Neonatal carriage of GBS at day 6 was associated with maternal carriage in the breast milk (aOR 3.75; 95% CI 1.32-10.65) and vaginal tract (aOR 3.42; 95% CI 1.27-9.22).Maternal colonization with S. aureus or GBS is a risk factor for bacterial colonization in newborns.
Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites
Authors: Andreas Agathangelidis, Anastasia Hadzidimitriou, Eva Minga, Lesley-Ann Sutton, Eleftheria Polychronidou, Tait D. Shanafelt, Zadie Davis, Xiao-Jie Yan, Karla Plevova, Myriam Boudjoghra, Alba Navarro, Davide Rossi, Lone Bredo Pedersen, Vasilis Bikos, Panagiotis Baliakas, Lydia Scarfò, Mattias Mattsson, Aliki Xochelli, Paola Francia di Celle, Krzysztof Giannopoulos, Katrina Vanura, Ludo Evers, Silvio Veronese, Monica Facco, Panagiotis Moschonas, Vojtech Bystry, Teodora Karan-Djurasevic, Maria Roumelioti, Sonja Pavlovic, Larry Mansouri, Charles Chu, Evangelia Stalika, Veronique Giudicelli, Panagiotis Panagiotidis, Andrey Sudarikov, Achilles Anagnostopoulos, Livio Trentin, Mark Catherwood, Marco Montillo, Niki Stavroyianni, Gianluca Gaidano, Elias Campo, Carsten Utoft Niemann, Anton W. Langerak, Sarka Pospisilova, Marie-Paule Lefranc, Ulrich Jaeger, Arnon Kater, Christiane Pott, Nicholas Chiorazzi, David Oscier, Diane F. Jelinek, Stephan Stilgenbauer, Michael Hallek, Dimitrios Tzovaras, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos
Journal: Blood (2016)
Diagnosis of Western Red Cedar Asthma Using a Blood-based Gene Expression Biomarker Panel
Authors: Chen Xi Yang, Amrit Singh, Young Woong Kim, Edward M. Conway, Christopher Carlsten, Scott J. Tebbutt
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Abstract Western red cedar asthma is the most common form of occupational asthma in the Pacific Northwest region of North America and is caused by a low molecular weight molecule, plicatic acid, found in western red cedar wood. In the present study, peripheral whole blood transcriptomics was used to identify biomarker panels that distinguish asthmatic individuals who are sensitive to plicatic acid from asthmatic individuals who are not sensitive to plicatic acid. These findings suggest that blood may be used as a resource to diagnose western red cedar asthma.
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Authors: Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot, Martin Bendszus, Jaap C Reijneveld, Frederick Dhermain, Pim French, Christine Marosi, Colin Watts, Ingela Oberg, Geoffrey Pilkington, Brigitta G Baumert, Martin J B Taphoorn, Monika Hegi, Manfred Westphal, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick
Journal: The Lancet Oncology (2017)
Energy Metabolism of the Osteoblast: Implications for Osteoporosis
Authors: Wen-Chih Lee, Anyonya R. Guntur, Fanxin Long, Clifford J. Rosen
Journal: Endocrine Reviews (2017)

Osteoblasts, the bone-forming cells of the remodeling unit, are essential for growth and maintenance of the skeleton. Clinical disorders of substrate availability (e.g., diabetes mellitus, anorexia nervosa, and aging) cause osteoblast dysfunction, ultimately leading to skeletal fragility and osteoporotic fractures. Conversely, anabolic treatments for osteoporosis enhance the work of the osteoblast by altering osteoblast metabolism. Emerging evidence supports glycolysis as the major metabolic pathway to meet ATP demand during osteoblast differentiation. Glut1 and Glut3 are the principal transporters of glucose in osteoblasts, although Glut4 has also been implicated. Wnt signaling induces osteoblast differentiation and activates glycolysis through mammalian target of rapamycin, whereas parathyroid hormone stimulates glycolysis through induction of insulin-like growth factor-I. Glutamine is an alternate fuel source for osteogenesis via the tricarboxylic acid cycle, and fatty acids can be metabolized to generate ATP via oxidative phosphorylation although temporal specificity has not been established. More studies with new model systems are needed to fully understand how the osteoblast utilizes fuel substrates in health and disease and how that impacts metabolic bone diseases.
A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2<sup>+ </sup>metastatic breast cancer.
Authors: Binghe Xu, Fei Ma, Shanshan Chen, Qiao Li, Fan Yang, Yifan Zhang, Xiaoyan Chen, Dafang Zhong, Ge Zhang
Journal: Journal of Clinical Oncology (2015)

e11596 Background: Pyrotinib is a novel small molecule irreversible pan-tyrosine kinase inhibitor with IC50values of 8.1 nM at HER2 and 5.6 nM at EGFR1, respectively. Methods: The Phase I study was conducted to determine tolerability, safety, and pharmacokinetic profile of pyrotinib in Chinese patients with HER2+ metastatic breast cancer (n = 36). The majority (75%) of patients were previously treated with multiple lines ( ≤ 5) of anti-tumor regimens including trastuzumab and trastuzumab naive. The dose-escalation study was conducted at 80, 160, 240, 320 and 400mg levels in patients received orally pyrotinib once daily on a 28-day cycle. Results: In general, pyrotinib was safe and well tolerated when administered to patients for 2 cycles. Only 3 subjects experienced dose limiting toxicity, which was grade III diarrhea with 1 of 9 in 320mg and 2 of 8 in 400mg cohorts. The majority of AEs occurred was grade I and II, and the most common adverse events included diarrhea(41.7%), nausea(8.3%), rash (8.3%), and oral cavity ulcer (8.3%). The incidence and severity of diarrhea were dose-dependent, and manageable without dose modifications or discontinuation. In a dose range of 80mg-400mg, steady–state pharmacokinetic parameters were the Tmax of 2-4 hrs and T1/2 of 11.4-15.9 hrs, respectively, and demonstrated a favorable PK profile as evidenced by high exposure of pyrotinib with Cmax of 43-175 ng/mL and AUC0-24of 549-2660 ng*h/mL without significant accumulation after repeated dosing. The antitumor responses of pyrotinib (80mg-400mg) were also obtained with an overall ORR of 47.2% and DCR of 80.6 % in 36 patients (17PR, 12SD, 7PD) following the first 2-cycles. Based on tolerability, PK and efficacy data, 320 mg and 400mg of pyrotinib once daily could be considered a recommended regimen for Phase II studies. However, small sample sizes in each cohort warrant further investigation of its long term safety and efficacy in a large patient population. Conclusions: The present study demonstrated promising results of this novel irreversible pan-tyrosine kinase inhibitor, pyrotinib, in Chinese breast cancer patients with HER2 + metastatic disease. Clinical trial information: NCT01937689.
Allocation of Physician Time in Ambulatory Practice
Authors: David P. Serota
Journal: Annals of Internal Medicine (2017)

Letters2 May 2017Allocation of Physician Time in Ambulatory PracticeDavid P. Serota, MDDavid P. Serota, MDFrom Emory University, Atlanta, Georgia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0075 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Sinsky and colleagues (1) provide important quantification of the amount of hours spent on direct patient care versus EHR work in modern ambulatory practice. Much of the lay press' response to this study (2) has characterized the modern physician's work as clerical paper-pushing. A pessimistic interpretation of these data portrays the downfall of the “Good Doctor” at the hands of his or her own technologic advances.The amount of EHR interaction required of all physicians is increasing and will probably continue to do so. Sinsky and colleagues' study raises important questions about physician satisfaction and compensation for ...References1. Sinsky C, Colligan L, Li L, Prgomet M, Reynolds S, Goeders L, et al. Allocation of physician time in ambulatory practice: a time and motion study in 4 specialties. Ann Intern Med. 2016;165:753-60. [PMID: 27595430]. doi:10.7326/M16-0961 LinkGoogle Scholar2. Lee BY. Doctors wasting over two-thirds of their time doing paperwork. 7 September 2016. Accessed at www.forbes.com/sites/brucelee/2016/09/07/doctors-wasting-over-two-thirds-of-their-time-doing-paperwork/#68b1611f6e5d on 20 December 2016. Google Scholar3. Weinberg RB. Coeur d'Alene. Ann Intern Med. 2016;165:822-3. [PMID: 27919094]. doi:10.7326/M16-0258 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Emory University, Atlanta, Georgia.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0075. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAllocation of Physician Time in Ambulatory Practice: A Time and Motion Study in 4 Specialties Christine Sinsky , Lacey Colligan , Ling Li , Mirela Prgomet , Sam Reynolds , Lindsey Goeders , Johanna Westbrook , Michael Tutty , and George Blike Allocation of Physician Time in Ambulatory Practice Steven Bishop , Jeffrey Kushinka , and Shin-Ping Tu Allocation of Physician Time in Ambulatory Practice Christine Sinsky , Michael Tutty , and Lacey Colligan Allocation of Physician Time in Ambulatory Practice Join Y. Luh Metrics 2 May 2017Volume 166, Issue 9Page: 683KeywordsChartsConflicts of interestData managementDisclosurePatientsRunning ePublished: 2 May 2017 Issue Published: 2 May 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
New law to control prices of generic drugs
Authors: Deborah Cohen
Journal: BMJ (2017)

The UK parliament has passed new legislation to close a loophole that allowed companies to raise the prices of unbranded generic drugs.

The Health Services Medicinal Supplies (Costs) Act will give the government the power to control the prices of generic drugs if it believed excessive prices were being charged. For unbranded generic drugs, the government had relied on the market to keep prices down.

A recent Organisation for Economic Co-operation and Development report said that average generic drug prices in the UK are the …
High velocity suspension flame spraying (HVSFS) of metal doped bioceramic coatings
Authors: P. Krieg, A. Killinger, R. Gadow, S. Burtscher, A. Bernstein
Journal: Bioactive Materials (2017)

•Bioceramic coatings doped with metals for antibacterial effect.•Combination of suspension and precursor flame spraying.•Successful deposition of submicron metallic particles in bioceramic matrix.